Compare Tilray Brands Inc (TLRY) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tilray Brands Inc vs Xpeng Inc - ADR — how do they compare? Tilray Brands Inc trades at $3.54 (market cap $530.54M), while Xpeng Inc - ADR trades at $9.9 (market cap $9.16B). The key difference: Xpeng Inc - ADR is far larger — about 17.3× Tilray Brands Inc's market cap, and Tilray Brands Inc is more actively traded (9,099,075 versus 5,030,325). Which is the better fit depends on your goals — on Pluang, investors hold Tilray Brands Inc for 31 Days and Xpeng Inc - ADR for 80 Days on average.
| TLRY | XPEV | |
|---|---|---|
Market Cap | $530.54M | $9.16B |
Volume | 9,099,075 | 5,030,325 |
Sector | Health | Consumer Cyclical |
52-Week High | $21.00 | $28.07 |
52-Week Low | $3.57 | $9.25 |
Typical Hold Time | 31 Days | 80 Days |
Enterprise Value | $684.46M | $11.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Tilray Brands (TLRY) trades at $3.59, down 3.36% on the day and near 52-week lows, with bearish technical indicators dominating. The company reported $821 million in revenue for 2025 but posted a massive $2.19 billion net loss due to impairment charges. Recent earnings have consistently missed expectations, though analyst consensus remains cautiously optimistic with a $65.01 price target. The stock faces significant headwinds from ongoing profitability challenges and cannabis industry volatility.
TLRY presents a high-risk opportunity with potential upside if management can achieve profitability and capitalize on cannabis reform catalysts. However, persistent losses, negative cash flow, and competitive pressures create substantial downside risk. Investors should weigh the speculative nature against potential regulatory catalysts in the coming months.
XPeng (XPEV) trades at $9.55, down 0.31% with a bearish technical signal. The company shows strong revenue growth to $76.72B in 2025 but remains unprofitable with a net margin of -4.14%. Recent vehicle deliveries of 41,256 in September 2026 and the upcoming G9L SUV launch at the Paris Motor Show highlight expansion efforts. Analyst consensus is bullish with a $17.55 price target, though earnings misses in Q1 and Q2 2026 raise execution concerns.
The stock presents a high-risk, high-reward opportunity. Significant revenue growth and analyst optimism are offset by persistent losses and competitive pressures. Key catalysts include successful global expansion and profitability improvements, while risks involve execution missteps and macroeconomic headwinds in the EV sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
